KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortizatization of Intangibles (2016 - 2020)

Historic Amortizatization of Intangibles for TherapeuticsMD (TXMD) over the last 11 years, with Q1 2020 value amounting to $63155.0.

  • TherapeuticsMD's Amortizatization of Intangibles rose 5615.42% to $63155.0 in Q1 2020 from the same period last year, while for Mar 2020 it was $220304.0, marking a year-over-year increase of 6725.05%. This contributed to the annual value of $197593.0 for FY2019, which is 7567.88% up from last year.
  • According to the latest figures from Q1 2020, TherapeuticsMD's Amortizatization of Intangibles is $63155.0, which was up 5615.42% from $57387.0 recorded in Q4 2019.
  • In the past 5 years, TherapeuticsMD's Amortizatization of Intangibles ranged from a high of $63155.0 in Q1 2020 and a low of $11234.0 during Q1 2016
  • In the last 5 years, TherapeuticsMD's Amortizatization of Intangibles had a median value of $21197.0 in 2018 and averaged $29369.6.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first surged by 2008.13% in 2017, then skyrocketed by 9537.18% in 2019.
  • TherapeuticsMD's Amortizatization of Intangibles (Quarter) stood at $15985.0 in 2016, then increased by 20.08% to $19195.0 in 2017, then surged by 84.17% to $35351.0 in 2018, then skyrocketed by 62.33% to $57387.0 in 2019, then grew by 10.05% to $63155.0 in 2020.
  • Its Amortizatization of Intangibles stands at $63155.0 for Q1 2020, versus $57387.0 for Q4 2019 and $51259.0 for Q3 2019.